


Express Mail No.: EV 392157521 US
Date of Deposit: October 8, 2004



Page 1 of 5
Attorney Docket No.: 23239-558 A CIP

Please type a plus sign (+) in this box



Modified Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number	10/829,504
	Filing Date	April 21, 2004
	First Named Inventor	Epstein
	Group Art Unit	1632
	Examiner Name	Not Yet Assigned
	Attorney Docket Number	23239-558A

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
AS	*A1	3,710,795	01/16/73	Higuchi et al.	128	260	
	*A2	5,262,564	11/16/93	Kun et al.	562	430	
	*A3	5,270,163	12/14/93	Gold et al.	435	6	
	*A4	5,475,096	12/12/95	Gold et al.	536	23.1	
	*A5	5,496,938	03/05/96	Gold et al.	536	22.1	
	*A6	5,567,588	10/22/96	Gold et al.	435	6	
	*A7	5,580,737	12/03/96	Polisky et al.	435	6	
	*A8	5,589,332	12/31/96	Shih et al.	435	6	
	*A9	5,637,459	06/10/97	Burke et al.	435	6	
	*A10	5,648,214	07/15/97	Nieuwlandt et al.	435	6	
	*A11	5,660,985	08/26/97	Pieken et al.	435	6	
	*A12	5,668,264	09/16/97	Janjic et al.	536	23.1	
	*A13	5,672,695	09/30/97	Eckstein et al.	536	24.5	
	*A14	5,674,685	10/07/97	Janjic et al.	435	6	
	*A15	5,674,980	10/07/97	Frankel et al.	530	350	
	*A16	5,683,867	11/04/97	Biesecker et al.	435	6	
	*A17	5,698,687	12/16/97	Eckstein et al.	536	25.3	
	*A18	5,705,337	01/06/98	Gold et al.	435	6	
	*A19	5,707,796	01/13/98	Gold et al.	435	6	
	*A20	5,763,177	06/09/98	Gold et al.	435	6	
	*A21	5,804,604	09/08/98	Frankel et al.	530	324	
	*A22	5,817,635	10/06/98	Eckstein et al.	514	44	
	*A23	5,834,186	11/10/98	George et al.	435	6	
	*A24	5,859,228	01/12/99	Janjic et al.	536	24.3	
	*A25	5,958,691	09/28/99	Pieken et al.	435	6	
	*A26	6,011,020	01/04/00	Gold et al.	514	44	
	*A27	6,051,698	04/18/00	Janjic et al.	536	24.31	
	*A28	6,207,646 B1	03/27/01	Krieg et al.	514	44	
	*A29	6,207,816 B1	03/27/01	Gold et al.	536	24.1	
	*A30	6,214,806 B1	04/10/01	Krieg et al.	514	44	
	*A31	6,229,002 B1	05/08/01	Janjic et al.	536	23.1	
	*A32	6,239,116 B1	05/29/01	Krieg et al.	514	44	
	*A33	6,426,434 B1	07/30/02	Yoshida et al.	564	71	
	*A34	6,429,199 B1	08/06/02	Krieg et al.	514	44	

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
PS	*A35	6,498,148 B1	12/24/02	Raz	514	44	
PS	*A36	6,514,948 B1	02/04/03	Raz et al.	514	44	
PS	*A37	6,653,292 B1	11/25/03	Krieg et al.	514	44	

FOREIGN PATENT DOCUMENTS							
Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes	Translation No	
PS	*B1	WO 91/19813	The Univ. of Colorado Foundation, Inc.	12/26/91			
	*B2	WO 92/07065	Maxplanck-Gesellschaft Zur Förderung Der Wissenschaften	04/30/92			
	*B3	WO 98/08974	Intelligene Ltd.	03/05/98			
	*B4	WO 98/18480	Nexstar Pharmaceuticals, Inc.	05/07/98			
	*B5	WO 98/27104	Yale University	06/25/98			
	*B6	WO 99/31276	Nexstar Pharmaceuticals, Inc.	06/24/99			
	*B7	WO 00/70329	Brandeis University	11/23/00			
	*B8	WO 01/66721 A2	Ribozyme Pharmaceuticals, Inc.	09/13/01			
	*B9	WO 02/22882 A2	Archemix Corporation	03/21/02			
	*B10	WO 03/014375 A2	Archemix Corporation	02/20/03			

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
PS	*C1	Agrawal et al. <i>Ciba Found. Symp.</i> , 209:60-75 (1997)
	*C2	Akhtar et al. <i>Trends Pharmacol. Sci.</i> , 18:12-18 (1997)
	*C3	Antopolsky et al. <i>Bioconjug. Chem.</i> , 10(4):598-606 (1999)
	*C4	Astriab-Fisher et al. <i>Biochem. Pharmacol.</i> , 60(1):83-90 (2000)
	*C5	Bell et al. <i>In Vitro Anim. Cell. Dev. Biol.</i> , 35(9):533-542 (1999)
	*C6	Breaker R.R. <i>Curr. Opin. Biotech.</i> , 7:442-448 (1996)
	*C7	Breaker R.R. <i>Chem. Rev.</i> , 97:371-390 (1997)
	*C8	Breaker R.R. <i>Curr. Opin. Chem. Biol.</i> , 1:26-31 (1997)
	*C9	Breaker R.R. <i>Nat. Biotech.</i> , 15:427-431 (1997)
	*C10	Breaker R.R. <i>Intracellular Ribozyme Applications in Principles and Protocols</i> , pgs. 1-19; Horizon Scientific Press, Wymondham UK, Rossi and Couture, eds., (1999)
	*C11	Breaker R.R. <i>Curr. Opin. Biotech.</i> , 13:31-39 (2002)
	*C12	Carmi et al. <i>Chem. & Biol.</i> , 3:1039-1046 (1996)
	*C13	Carrasquillo et al. <i>Invest. Ophthalmol. Vis. Sci.</i> , 44(1):290-299 (2003)
	*C14	Chen et al. <i>Proc. Natl. Acad. Sci. USA</i> , 100(16):9226-9231 (2003)
	*C15	Cotten et al. <i>Nucl. Acids Res.</i> , 19(10):2629-2635 (1991)
	*C16	Crooke S.T. <i>Adv. Pharmacol.</i> , 40:1-49 (1997)
	*C17	Daniels et al. <i>Anal. Biochem.</i> , 305(2):214-226 (2002)
	*C18	De Rijk et al. <i>Nucl. Acids Res.</i> , 25(22):4679-4684 (1997)
	*C19	Ellington et al. <i>Nature</i> , 346(6287):818-822 (1990)
	*C20	Froehner et al. <i>Nucl. Acids Res.</i> , 14(13):5399-5407 (1986)

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	*C21	Froehler et al. <i>Tet. Lett.</i> , 27(46):5575-5578 (1986)
	*C22	Gold L. <i>Nat. Biotech.</i> , 20: 671-672 (2002)
	*C23	Golub et al. <i>Cell</i> , 77(2):307-316 (1994)
	*C24	Green et al. <i>Chem. Biol.</i> , 2:683-695 (1995)
	*C25	Greenwald et al. <i>J. Org. Chem.</i> , 60:331-336 (1995)
	*C26	Griffin et al. <i>Gene</i> , 137(1):25-31 (1993)
	*C27	Grindel et al. <i>Antisense Nucl. Acid Drug Dev.</i> , 8(1):43-52 (1998)
	*C28	Hamaguchi et al. <i>Anal. Biochem.</i> , 294:126-131 (2001)
	*C29	Harris et al. <i>Nat. Rev. Drug Discov.</i> , 2(3):214-221 (2003)
	*C30	Hartig et al. <i>Nat. Biotech.</i> , 20:717-722 (2002)
	*C31	Heinreich et al. <i>Science</i> , 299(5607):708-710 (2003)
	*C32	Hirose et al. <i>Tet. Lett.</i> , 28:2449-2452 (1978)
	*C33	Hobbs et al. <i>Biochem.</i> , 12(25):5138-5145 (1973)
	*C34	Jaeger et al. <i>Proc. Natl. Acad. Sci. USA</i> , 86:7706-7710 (1989)
	*C35	Jain et al. <i>Cancer Res.</i> , 47(12):3039-3051 (1987)
	*C36	Jain et al. <i>Adv. Drug Deliv.</i> , 26:71-90 (1997)
	*C37	Jellinek et al. <i>Biochem.</i> , 34(36):11363-11372 (1995)
	*C38	Jenison et al. <i>Antisense Nucl. Acid Drug Dev.</i> , 8(4):265-279 (1998)
	*C39	Jenne et al. <i>Nat. Biotech.</i> , 19:56-61 (2001)
	*C40	Khati et al. <i>J. Virol.</i> , 77(23):12692-12698 (2003)
	*C41	Koizumi et al. <i>Nucl. Acids Symp. Ser.</i> , 42:275-276 (1999)
	*C42	Koizumi et al. <i>Nat. Struct. Biol.</i> , 6(11):1062-1071 (1999)
	*C43	Kraus et al. <i>J. Immunol.</i> , 160:5209-5212 (1998)
	*C44	Krieg A.M. <i>Annu. Rev. Immunol.</i> , 20:709-760 (2002)
	*C45	Lebedeva et al. <i>Eur. J. Pharm. Biopharm.</i> , 50(1):101-119 (2000)
	*C46	Li et al. <i>Curr. Opin. Struct. Biol.</i> , 9:315-323 (1999)
	*C47	Li et al. <i>Proc. Natl. Acad. Sci. USA</i> , 96:2746-2751 (1999)
	*C48	Lin et al. <i>Nucl. Acids Res.</i> , 22(24):5529-5234 (1994)
	*C49	Magnusson et al., <i>Blood</i> , 98(8):2518-2525 (2001)
	*C50	Manoharan M. <i>Antisense Nucl. Acid Drug Dev.</i> , 12(2):103-128 (2002)
	*C51	Marshall et al., <i>Nat. Struct. Biol.</i> , 6(11):992-994 (1999)
	*C52	Mathews et al. <i>J. Mol. Biol.</i> , 288(5):911-940 (1999)
	*C53	Monteith et al. <i>Toxicol. Pathol.</i> , 27(1):8-13 (1999)
	*C54	O'Brien et al. <i>Genes Chromosomes & Cancer</i> , 23(2):187-193 (1998)
	*C55	Ostman et al. <i>Adv. Cancer Res.</i> , 80:1-38 (2001)
	*C56	Padilla et al. <i>Nucl. Acids Res.</i> , 30(24):e138 (2002)
	*C57	Pagratz et al. <i>Nat. Biotechnol.</i> , 15(1):68-73 (1997)
	*C58	Peng et al. <i>Antisense Nucl. Acid Drug Dev.</i> , 11(1):15-27 (2001)
	*C59	Picken et al. <i>Science</i> , 253:314-317 (1991)


OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	*C60	Pietersz et al. <i>Vaccine</i> , 19(11-12):1397-1405 (2001)
	*C61	Pietras et al. <i>Cancer Res.</i> , 61:2929-2934 (2001)
	*C62	Pietras et al. <i>Cancer Res.</i> , 62:5476-5484 (2002)
	*C63	Pietras et al. <i>Cancer Cell</i> , 3:439-443 (2003)
	*C64	Potyrailo et al. <i>Anal. Chem.</i> , 70:3419-3425 (1998)
	*C65	Reyderman et al. <i>Pharm. Res.</i> , 15(6):904-910 (1998)
	*C66	Richardson et al. <i>Biochem. Pharmacol.</i> , 59(9):1045-1052 (2000)
	*C67	Richardson et al. <i>Chem. Res. Toxicol.</i> , 15(7):922-926 (2002)
	*C68	Robertson et al. <i>Nucl. Acids Res.</i> , 28(8):1751-1759 (2000)
	*C69	Robertson et al. <i>Nat. Biotech.</i> , 17:62-66 (1999)
	*C70	Robertson et al. <i>Nat. Biotech.</i> , 19:650-655 (2001)
	*C71	Rothbard et al. <i>Nat. Med.</i> , 6(11):1253-1257 (2000)
	*C72	Rothbard J. <i>J. Med. Chem.</i> , 45(17):3612-3618 (2002)
	*C73	Ruckman et al. <i>J. Biol. Chem.</i> , 273(32):20556-20567 (1998)
	*C74	Sassanfar et al. <i>Nature</i> , 364:550-553 (1993)
	*C75	Seetharaman et al. <i>Nat. Biotech.</i> , 19:336-341 (2001)
	*C76	Seiwert et al. <i>Chem. & Biol.</i> , 7:833-843 (2000)
	*C77	Shimizu et al. <i>Cancer Res.</i> , 59:3719-3723 (1999)
	*C78	Simon et al. <i>Nat. Genet.</i> , 15:95-98 (1997)
	*C79	Smidt et al. <i>Nucl. Acids Res.</i> , 19(17):4695-4700 (1991)
	*C80	Smith et al. <i>Cell</i> , 89(5):669-672 (1997)
	*C81	Sood et al. <i>Nucl. Acids Res.</i> , 4(8):2757-2765 (1977)
	*C82	Soukup et al. <i>Proc. Natl. Acad. Sci. USA</i> , 96:3584-3589 (1999)
	*C83	Soukup et al. <i>RNA</i> , 5:1308-1325 (1999)
	*C84	Soukup et al. <i>Structure</i> , 7(7):783-791 (1999)
	*C85	Soukup et al. <i>Tren. Biotech.</i> , 17:469-476 (1999)
	*C86	Soukup et al. in <i>Ribozyme Biochem. Biotech.</i> , Eaton Publishing, Chapter 8, pgs. 149-170, Krupp & Gaur, eds. (2000)
	*C87	Soukup et al. <i>RNA</i> , 7:524-536 (2001)
	*C88	Soukup et al. <i>J. Mol. Biol.</i> , 298:623-632 (2000)
	*C89	Sproat et al. <i>Nucl. Acids Res.</i> , 19(4):733-738 (1991)
	*C90	Srinivasan et al. <i>J. Clin. Lab. Anal.</i> , 9(2):129-137 (1995)
	*C91	Tang et al. <i>Chem. & Biol.</i> , 4:453-459 (1997)
	*C92	Tang et al. <i>Nucl. Acids Res.</i> , 26(18):4214-4221 (1998)
	*C93	Tang et al. <i>RNA</i> , 3:914-925 (1997)
	*C94	Tavitian et al. <i>Nat. Med.</i> , 4(4):467-471 (1998)
	*C95	Tucker et al. <i>J. Chromatography B</i> , 732:203-212 (1999)
	*C96	Tuerk et al. <i>Science</i> , 249(4968):505-510 (1990)
	*C97	Uhlmann et al. <i>Methods Enzymol.</i> , 313:268-284 (2000)
✓	*C98	Vaish et al. <i>Biochem.</i> , 42(29):8842-8851 (2003)

Express Mail No.: EV 392157521 US
Date of Deposit: October 8, 2004

Page 5 of 5
Attorney Docket No.: 23239-558 A CIP

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
J	*C99	Vives et al. <i>J. Biol. Chem.</i> , 272(25):16010-16017 (1997)
J	*C100	Watson et al. <i>Antisense Nucl. Acid Drug Dev.</i> , 10(2):63-75 (2000)
J	*C101	Wlotzka et al. <i>Proc. Natl. Acad. Sci. USA</i> , 99(13):8898-8902 (2002)
J	*C102	Zubin et al. <i>FEBS Lett.</i> , 456(1):59-62 (1999)
↓	*C103	Zuker M. <i>Science</i> , 244:48-52 (1989)

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. 10/829,504, filed April 21, 2004, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	10/4/07
-----------------------	---	--------------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

TRA 1965293v1

Express Mail Label No.: EV 392124086 US
Date of Deposit: December 10, 2004



Page 1 of 4
Attorney Docket No.: 23239-558 A

Please type a plus sign (+) in this box




Modified Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number	10/829,504
	Filing Date	April 21, 2004
	First Named Inventor	David Epstein
	Group Art Unit	1632
	Examiner Name	Not Assigned
	Attorney Docket Number	23239-558A

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
B ↓	A38	4,683,195	07/28/87	Mullis	1	1	
	A39	4,935,363	06/19/90	Brown et al.			
	A40	5,070,010	12/03/91	Hsu			
	A41	5,459,015	10/17/95	Janjic et al.			
	A42	5,635,615	06/03/97	Allen et al.			
	A43	5,654,151	08/05/97	Allen et al.			
	A44	5,723,323	03/03/98	Kauffman et al.			
	A45	5,723,594	03/03/98	Janjic et al.			
	A46	5,763,173	06/09/98	Gold et al.			
	A47	5,811,533	09/22/98	Gold et al.			
	A48	5,849,479	12/15/98	Janjic et al.			
	A49	6,013,443	01/11/00	Heiliq et al.			
	A50	6,020,130	02/01/00	Gold et al.			
	A51	6,168,778	01/02/01	Janjic et al.			
	A52	6,426,335	07/30/02	Janjic et al.			
	A53	6,465,188	10/15/02	Gold et al.			
	A54	6,582,918	06/24/03	Janjic et al.			
A55	6,696,252	02/24/04	Gold et al.				
↓	A56	6,699,843B2	03/02/04	Pietras et al.			
U.S. PUBLISHED APPLICATION DOCUMENTS							
Exam Initials	Cite No.	U.S. Published Application No.	Published Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
B ↓	A57	2002/0034506A1	03/21/02	Pietras et al.	1	1	
	A58	20030036642A1	02/20/03	Janjic et al.			
	A59	20030114404A1	06/19/03	Janjic et al.			
	A60	20030176680A1	09/18/03	Gold et al.			
	A61	20030180744A1	09/25/03	Gold et al.			

FOREIGN PATENT DOCUMENTS						
Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No	
BS	B11	UK	2183661A	Ballivet, M. et al.	06/10/87	
	B12	PCT	WO89/06694	Trustees of the University of Pennsylvania	07/27/89	
	B13	PCT	WO0187351A1	Gilead Sciences, Inc.	11/22/01	
	B14	PCT	WO91/14436	ISIS Pharmaceuticals, Inc.	10/03/91	
	B15	PCT	WO92/05285	Fred Hutchinson Cancer Research Center	04/02/92	
	B16	PCT	WO92/14842	Gilead Sciences, Inc.	09/03/92	
	B17	PCT	WO92/14843	Gilead Sciences, Inc.	09/03/92	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
BS	C104	AGRAWAL, S., ET AL., Antisense and/or Immunostimulatory Oligonucleotide Therapeutics, Current Cancer Drug Targets, 1:197-209 (2001)
	C105	ANDRAKE (1988) Proc. Natl. Acad. Sci. USA 85:7942
	C106	BALASUBRAMANIAN, V. ET AL., Role of Platelet Derived Growth Factor in Vascular Remodeling during Pulmonary Hypertension the Ovine Fetus, Am J. Physiol Lung Cell Mol Phy, 284:L826-33 (2003)
	C107	BERGERS, G., ET AL. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors, Journal of Clin Invest Vol. 111:9: 1287-95 (May 2003)
	C108	BINKLEY, J. ET AL., RNA Ligands to Human Nerve Growth Factor, Nucleic Acids Research (1995), Vol. 23, No. 16 pg. 3198-3205
	C109	CAREY ET AL., (1983) Biochem. 22(11):2601-10
	C110	CERCHIA, L., ET AL., Nucleic acid aptamers in cancer medicine, Federation of European Biochemical Societies, 528, 12-16 (2002)
	C111	CLOAD, S., The Aptamer Therapeutics Company, RNA in Drug Development, San Diego, CA., Nov. 10, 2003
	C112	COHEN ET AL., (1969) Proc. Natl. Acad. Sci. USA 63:458-64
	C113	DAVIS, J., ET AL., Identifying Consensus Patterns and Secondary Structure in SELEX Sequence Sets, Methods in Enzymology, Vol. 267 (18) 302-314, (1996)
	C114	DROLET, D. ET AL., Pharmacokinetics and Safety of an Anti-Vascular Endothelial Growth Factor Aptamer..., Pharmaceutical Research, Vol. 17, No. 12:1503-9 (2000)
	C115	ELLINGTON & SZOSTAK (1990) Abstracts of papers presented at the 1990 meeting on RNA Processing, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, p. 84
	C116	FITZWATER, T., ET AL., A Selex Primer, Methods in Enzymology, Vol. 267 (17) 275-301 (1996)
	C117	FLOEGE, J., ET AL., Novel Approach to Specific Growth Factor Inhibition in Vivo, American Journal of Pathology, Vol. 154, No. 1:169-179 (Jan. 1999)
	C118	FREDRIKSSON S., ET AL., Protein detection using proximity-dependent DNA Ligation assays, Nature Biotechnology, Vol. 20: 473-77 (May 2002)
	C119	GRATE, DILARA, PDGF Blockade data, AACR 2004, Orlando, Florida, March 27, 2004
	C120	GREEN, L.S. ET AL., Inhibitory DNA Ligands to Platelet Derived Growth Factor B-Chain, Biochemistry, 35:14413-14424 (1996)
	C121	GRIFFEN, R., ET AL., Simultaneous Inhibition of the Receptor Kinase Activity of Vascular Endothelial,


OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
		Fibroblast, and Platelet-derived Cancer Research 62: 1702-1706 (2002)
	C122	HUANG, J., ET AL., Highly Specific Antiangiogenic Therapy is Effective In Suppressing Growth of Experimental Wilms Tumors, J. of Pediatric Surgery, Vol. 36, No. 2:357-361 (2001)
	C123	JELLINEK, D., High-Affinity RNA Ligands to Basic Fibroblast Growth Factor Inhibit Receptor Binding, Proc. Nat'l Acad. Sci. USA, Vol. 90, pp. 11227-11231, December 1993
	C124	JELLINEK, D., Inhibition of Receptor Binding by High-Affinity RNA Ligands to Vascular Endothelial Growth Factor, Biochemistry, 1994, 33:10450-56
	C125	JOYCE (1989) Gene, RNA: Catalysis, Splicing, Evolution, 82:83
	C126	JOYCE & INNOUE (1989) Nucleic Acids Research 17:711-22
	C127	KACIAN ET AL. (1972) Proc. Natl. Acad. Sci. USA 69:3038-42
	C128	KADONAGA ET AL. (1986) Proc. Natl. Acad. Sci. USA 83:5889-93
	C129	KIM, E. ET AL., Potent VEGF Blockade Causes Regression of Coopted Vessels in a Model of Neuroblastoma, PNAS, August 20, 2002, Vol. 99, No. 17, pgs. 11399-11404
	C130	KINZLER & VOGELSTEIN (1989) Nucleic Acids Research 17:3645-53
	C131	KINZLER ET AL. (1990) Mol. Cell. Biol. 10:634-42
	C132	KRAMER ET AL. (1974) J. Mol. Biol. 89:719-36
	C133	LEPPANEN, OL, ET AL., Intimal Hyperplasia Recurs After Removal of PDGF-AB and-BB Inhibition in the Rat Carotid Artery Injury Model, Arterioscler Throm Vasc Biol. (Nov. 2000) 20:e89-e95
	C134	LESTIENNE ET AL. (1983) Biochimie. 65:49-52
	C135	LEVISOHN & SPIEGELMAN (1968) PNAS USA 60:866-72
	C136	LEVISOHN & SPIEGELMAN (1969) PNAS USA 63:805-11
	C137	MA AND PTASHNE (1987) Cell 51: 113-19
	C138	MANIATIS (1982) Molecular Cloning: a Laboratory Manual, page 118
	C139	MANIATIS ET AL. (1987) Science 236: 1237-45
	C140	MIELE ET AL. (1983) J. Mol. Biol. 171:281-95
	C141	MILLS ET AL. (1967) Proc. Natl. Acad. Sci. 58:217-220
	C142	MILLS ET AL. (1973) Science 180:916-27
	C143	MIN ET AL. (1988) Nucleic Acids Res. 16:5075-88
	C144	MUESING ET AL. (1985) Nature 313:450-58
	C145	OLIPHANT & STRUHL I (1987) Methods in Enzymology 155:568-82
	C146	OLIPHANT & STRUHL I (1988) Nucleic Acids Research 16:7673-83
	C147	OLIPHANT ET AL. (1986) Gene 44:177-83
	C148	OLIPHANT ET AL. (1989) Mol. Cell. Biol. 9:2944-49
	C149	ORGEL (1979) Proc. R. Soc. Lon. B205:435-42
	C150	OSTENDORF, T. ET AL., The Journal of Clinical Investigation, (October 1999), Vol. 104, Number 7:913-29
	C151	OSTENDORF, T. ET AL, J Am Soc Nephrol 12:909-918, 2001
	C152	OSTENDORF, T. ET AL., J Am Soc Nephrol 13: 658-667, 2002
	C153	OU ET AL. (1988) Science 239:295-97

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Exa m Initi als	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.	
	C154	RINGQUIST, S. ET AL., (1998) Cytometry 33:394-405	
	C155	ROBERTSON & JOYCE (1990) Nature 344:467-68	
	C156	ROMANIUK ET AL. (1987) Biochem. 26(6):1563-68	
	C157	SAFFHILL ET AL. (1970) J. Mol. Biol. 51 :531-39	
	C158	SAMBROOK ET AL. (1989) Molecular Cloning: A Laboratory Manual., Cold Spring Harbor, NY, section 8.9-8.10	
	C159	SJÖBLOM, T., Paracrine and Autocrine Functions of PDGF in Malignant Disease, Comprehensive Summaries of Uppsala Dissertations From the Faculty of Medicine (2002)	
	C160	SINGLETON ET AL., Dictionary of Microbiol. & Molec. Biol., Wiley & Sons, New York, NY, 2nd ed. p. 270	
	C161	SZOSTAK, A., Structure and Activity of Ribozymes, in Redesigning the Molecules of Life, (SA Benner ed.) Springer-Verlag Berlin Heidelberg, pp. 87-113 (1988)	
	C162	THIESEN & BACH (1990) Nucleic Acids Research 18:3203-9	
	C163	UHLENBECK ET AL. (1983) J. Biomolecular Structure and Dynamics 1 :539-52	
	C164	UHRBOM, L., ET AL., Int., J. Cancer: 85, 398-406 (2000)	
	C165	WATSON ET AL. (1987) Molecular Biology of the Gene. Benjamin/Cummings Publishing Co., Inc. California, pp. 267,295,323,361,394,396,397 and 405	
	C166	WILLIS, M., ET AL., Bioconjugate Chem. 1998, 9, 573-582	
	C167	WU, C. ET AL., Human Gene Therapy 14:849-860 (June 10, 2003)	
Examiner Signature			Date Considered 10/21/07

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.

Express Mail Label: EV 92131365 US
Date of Deposit: September 10, 2004



COPY

Page 1 of 3
Attorney Docket No.: 23239-547

Please type a plus sign (+) in this box

+

Modified Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number	10/762,915
	Filing Date	January 21, 2004
	First Named Inventor	Epstein
	Group Art Unit	1614
	Examiner Name	Not Yet Assigned
	Attorney Docket Number	23239-547

U.S. PATENT DOCUMENTS

Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
	A1	3,710,795	04/16/73	Higuchi, et al.	128	260	
	A2	5,262,564	11/16/93	Kun, et al.	382	430	
	A3	5,496,938	09/09/96	Gold, et al.	530	22.1	
	A4	5,567,588	10/22/96	Gold, et al.	435	6	
	A5	5,580,737	12/03/96	Pelley, et al.	435	6	
	A6	5,589,332	12/31/96	Shih, et al.	435	6	
	A7	5,637,459	06/10/97	Burke, et al.	435	6	
	A8	5,648,214	07/15/97	Nieuwandt, et al.	435	6	
	A9	5,660,983	08/26/97	Pleken, et al.	435	6	
	A10	5,668,264	09/16/97	Janjic, et al.	536	23.1	
	A11	5,674,683	10/07/97	Janjic, et al.	435	6	
	A12	5,683,867	11/04/97	Biesecker, et al.	435	6	
	A13	5,705,337	01/06/98	Gold, et al.	435	6	
	A14	5,707,796	01/13/98	Gold, et al.	435	6	
	A15	5,763,177	06/09/98	Gold, et al.	435	6	
	A16	5,834,186	11/10/98	George, et al.	435	6	
	A17	5,859,228	01/12/99	Janjic, et al.	536	24.3	
	A18	6,011,020	01/04/00	Gold, et al.	514	44	
	A19	6,051,698	04/18/00	Janjic, et al.	536	24.31	
	A20	6,207,816 B1	03/27/01	Gold, et al.	536	24.1	
	A21	6,229,002 B1	05/08/01	Janjic, et al.	536	23.1	

U.S. PUBLISHED APPLICATION DOCUMENTS

Exam Initials	Cite No.	U.S. Published Application No.	Published Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate


FOREIGN PATENT DOCUMENTS

Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes	Translation No
	B1	WO 98/08974	Intelligence Ltd.	03/05/98		
	B2	WO 98/48480	Nexstar Pharmaceuticals, Inc.	05/07/98		
	B3	WO 98/27104	Yale University	06/25/98		
	B4	WO 99/31276	Nexstar Pharmaceuticals, Inc.	6/24/99		
	B5	WO 00/70329	Brandels University	11/23/00		
	B6	WO 01/66724 A2	Ribozyme Pharmaceuticals, Inc.	09/13/01		
	B7	WO 02/22882 A2	Archemix Corporation	3/21/02		

BB	WO	03/014375-A2	Archemix Corporation	2/20/03		
OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS						
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.				
RS	C1	Belyea, et al., <i>Am. J. Phththalmol.</i> , 124(1):40-45 (1997).				
RS	C2	Blindish, et al., <i>Ophthalmol.</i> , 109(7):1336-1342 (2002).				
	C3	Breaker, R.R., <i>Curr. Opin. Biotech.</i> , 7:442-448 (1996).				
	C4	Breaker, R.R., <i>Chem. Rev.</i> , 97:371-390 (1997).				
	C5	Breaker, R.R., <i>Curr. Opin. Chem. Biol.</i> , 1:26-31 (1997).				
	C6	Breaker, R.R., <i>Nat. Biotech.</i> , 15:427-431 (1997).				
	C7	Breaker, R.R., <i>Intracellular Ribozyme Applications in Principles and Protocols</i> , pgs. 1-19; Horizon Scientific Press, Wymondham UK, Rossi and Couture, eds., (1999).				
	C8	Breaker, R.R., <i>Curr. Opin. Biotech.</i> , 13:31-39 (2002).				
RS	C9	Broadway, et al., <i>Invest. Ophthalmol. Vis. Sci.</i> , "Adjunctive anti-TGFβ2 human Mab as a novel agent to prevent scarring following phacotrabeculectomy", 43:E-Abstract 3331 (2002).				
	C10	Camli, et al. <i>Chem. & Biol.</i> , 3:1039-1040 (1996).				
	C11	Cordeiro, et al., <i>Invest. Ophthalmol. Vis. Sci.</i> , 40:1975-1982 (1999).				
	C12	Cordeiro, et al., <i>Gene Therapy</i> , 10(1):59-71 (2003).				
	C13	Cotten, et al., <i>Nucl. Acid Res.</i> , 19(10):2629-2635 (1991).				
	C14	Enaida, et al., <i>Fukushima J. Med. Sci.</i> , 44(1):43-52 (1998).				
	C15	Freehler, et al., <i>Nucl. Acid Res.</i> , 14(13):5309-5407 (1986).				
	C16	Freehler, et al., <i>Tet. Lett.</i> , 27(46):5575-5578 (1986).				
	C17	Gold, L., <i>Nat. Biotech.</i> , 20: 671-672 (2002).				
	C18	Greenwald, et al., <i>J. Org. Chem.</i> , 60(2):331-336 (1995).				
	C19	Hamaguchi, et al., <i>Anal. Biochem.</i> , 294:126-131 (2001).				
	C20	Harris, et al., <i>Nature Rev. Drug Discov.</i> , 2(3):214-221 (2003).				
	C21	Hartig, et al., <i>Nat. Biotech.</i> , 20:717-722 (2002).				
	C22	Hirose, et al., <i>Tet. Lett.</i> , 28:2449-2452 (1978).				
	C23	Hobbs, et al., <i>Biochem.</i> , 12(25):5138-5145 (1973).				
	C24	Jellinek, et al., <i>Biochem.</i> , 34(36):11363-11372 (1995).				
	C25	Jenne, et al., <i>Nat. Biotech.</i> , 19:56-61 (2001).				
	C26	Koizumi, et al., <i>Nucl. Acids Symp. Ser.</i> , 42:275-276 (1999).				
	C27	Koizumi, et al., <i>Nat. Struct. Biol.</i> , 6(11):1062-1071 (1999).				
	C28	Kraus, et al., <i>J. Immunol.</i> , 160:5209-5212 (1998).				
RS	C29	Kupin, et al., <i>Am. J. Ophthalmol.</i> , 119:30-39 (1995).				
	C30	Li, et al., <i>Curr. Opin. Struct. Biol.</i> , 9:315-323 (1999).				
	C31	Li, et al., <i>Proc. Natl. Acad. Sci. USA</i> , 96:2746-2751 (1999).				
	C32	Lin, et al., <i>Nucl. Acids Res.</i> , 22(24):5220-5234 (1994).				
	C33	Marshall, et al., <i>Nat. Struct. Biol.</i> , 6(11):992-994 (1999).				
	C34	Membrey, et al., <i>Br. J. Ophthalmol.</i> , 84:1154-1158 (2000).				
RS	C35	Ochiai, et al., <i>Jpn. J. Ophthalmol.</i> , 46(3):249-253 (2002).				
	C36	Padilla, et al., <i>Nucl. Acids Res.</i> , 30(24):6198 (2002).				
	C37	Pagratis, et al., <i>Nat. Biotechnol.</i> , 15(1):68-73 (1997).				


C38	Pleken, et al., <i>Science</i> , 253:314-317 (1991).
C39	Potyrailo, et al., <i>Anal. Chem.</i> , 70:3410-3425 (1998).
C40	Robertson, et al., <i>Nucl. Acids Res.</i> , 28(8):1751-1759 (2000).
C41	Robertson, et al., <i>Nat. Biotech.</i> , 17:62-66 (1999).
C42	Robertson, et al., <i>Nat. Biotech.</i> , 19:650-655 (2001).
C43	Sassanfar, et al., <i>Nature</i> , 364:550-553 (1993).
C44	Seetharaman, et al., <i>Nat. Biotech.</i> , 19:336-341 (2001).
C45	Seiwert, et al., <i>Chem. & Biol.</i> , 7:833-843 (2000).
C46	Good, et al., <i>Nucl. Acids Res.</i> , 4(8):2757-2765 (1977).
C47	Soukup, et al., <i>Proc. Natl. Acad. Sci. USA</i> , 96:3584-3589 (1999).
C48	Soukup, et al., <i>RNA</i> , 5:1308-1325 (1999).
C49	Soukup, et al., <i>Structure</i> , 7(7):783-791 (1999).
C50	Soukup, et al., <i>Tren. Biotech.</i> , 17:469-476 (1999).
C51	Soukup, et al., in <i>Ribozyme Biochem. Biotech.</i> , Eaton Publishing, Chapter 8, pgs. 149-170, Krupp & Gaur, eds. (2000).
C52	Soukup, et al., <i>RNA</i> , 7:524-536 (2001).
C53	Soukup, et al., <i>J. Mol. Biol.</i> , 298:623-632 (2000).
C54	Sproat, et al., <i>Nucl. Acids Res.</i> , 19(4):733-738 (1991).
C55	Tang, et al., <i>Chem. & Biol.</i> , 4:453-459 (1997).
C56	Tang, et al., <i>Nucl. Acids Res.</i> , 26(18):4214-4221 (1998).
C57	Tang, et al., <i>RNA</i> , 3:914-925 (1997).
C58	Tripathi, et al., <i>Exp. Eye Res.</i> , 58(5):523-528 (1994).
C59	Tucker, et al., <i>J. Chromatography B.</i> , 732:203-212 (1999).

A copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	10/10/07
-----------------------	---	--------------------	----------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Express Mail No.: EX 392157668 US
Date of Deposit: November 10, 2004



Please type a plus sign (+) in this box



COPY

Page 1 of 2
Attorney Docket No.: 23239-541

PTO/SB (12-97)

Approved for use through 9/30/00, OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Modified Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number	10/718,833
	Filing Date	November 21, 2003
	First Named Inventor	Wilson
	Group Art Unit	1645
	Examiner Name	Not Yet Assigned
	Attorney Docket Number	23239-541

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
	A1	5,270,103	12/14/93	Gold et al.	435	6	
	A2	5,475,096	12/12/95	Gold et al.	536	23.1	
	A3	5,496,938	03/05/96	Gold et al.	536	32.1	
	A4	5,567,588	10/22/96	Gold et al.	435	6	
	A5	5,580,737	12/03/96	Polisky et al.	435	6	
	A6	5,637,459	06/10/97	Burke et al.	435	6	
	A7	5,648,214	07/15/97	Nieuwlandt et al.	435	6	
	A8	5,660,985	08/20/97	Picken et al.	435	6	
	A9	5,672,695	09/30/97	Eckstein et al.	536	24.3	
	A10	5,683,867	11/04/97	Biesecker et al.	435	6	
	A11	5,698,687	12/16/97	Eckstein et al.	536	25.3	
	A12	5,705,337	01/06/98	Gold et al.	435	6	
	A13	5,707,796	01/13/98	Gold et al.	435	6	
	A14	5,763,177	06/09/98	Gold et al.	435	6	
	A15	5,817,635	10/06/98	Eckstein et al.	514	44	
	A16	5,859,228	01/12/99	Janjic et al.	536	24.3	
	A17	5,958,691	09/28/99	Picken et al.	435	6	
	A18	6,011,020	01/04/00	Gold et al.	514	44	
	A19	6,051,698	04/18/00	Janjic et al.	536	24.3	
PC	A20	6,346,611 B1	02/12/02	Pagratis et al.	536	23.1	
U.S. PUBLISHED APPLICATION DOCUMENTS							
Exam Initials	Cite No.	U.S. Published Application No.	Published Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
B	A21	2002/0025941 A1	02/28/02	Meyer	514	44	
B	A22	2002/0034506 A1	03/21/02	Pietras et al.	424	94.63	
B	A23	2002/0034757 A1	03/21/02	Cubicciotti	435	6	

FOREIGN PATENT DOCUMENTS						
Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No	
	B1	WO 91/19813	THE UNIVERSITY OF COLORADO FOUNDATION, INC.	12/26/91		
	B2	WO 92/07065	MAXPLANCK GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN	04/30/92		
	B3	WO 98/18480	NEXSTAR PHARMACEUTICALS, INC.	05/07/98		


OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C1	Cotten et al. Nucl. Acids Res., 19(10):2629-2635 (1991)
	C2	Prochler et al. Nucl. Acids Res., 14(13):3399-3407 (1986)
	C3	Prochler et al. Tet. Lett., 27(46):5575-5578 (1986)
	C4	Hirose et al. Tet. Lett., 28:2449-2452 (1978)
	C5	Hobbs et al. Biochem., 12(25):5138-5145 (1973)
	C6	Jellinek et al., Biochem., 34(36):11363-11372 (1995)
	C7	Kraus et al. J. Immunol., 160:5209-5212 (1998)
	C8	Lin et al. Nucl. Acids Res., 22(24):5229-5234 (1994)
	C9	Pagratz et al. Nat. Biotechnol., 15(1):68-73 (1997)
	C10	Pleken, et al., Science, 253:314-317 (1991)
	C11	Sood et al. Nucl. Acids Res., 4(8):2737-2765 (1977)
	C12	Sproat et al. Nucl. Acids Res., 19(4):733-738 (1991)
	C13	Tucker et al. Chromatography B., 732:203-212 (1999)
PC	C14	International Search Report for PCT/US03/37338, mailing date: August 23, 2004.

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	06/10/07
-----------------------	---	--------------------	----------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.



Express Mail Label: EV 39213156 US
Date of Deposit: August 18, 2004

COPY

Page 1 of 2
Attorney Docket No.: 23239-531 CIP

Please type a plus sign (+) in this box

+

Modified Form 1449/PTO				Application Number		10/826,077	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Filing Date		April 15, 2004	
				First Named Inventor		Stanton	
				Group Art Unit		1645	
				Examiner Name		Not Yet Assigned	
				Attorney Docket Number		23239-531 CIP	
U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
	*A1	5,589,332	12/31/96	Shih, et al.	435	6	
	*A2	5,683,867	11/04/97	Biesecker, et al.	435	6	
	*A3	5,705,337	01/06/98	Gold, et al.	435	6	
	*A4	5,723,504	03/03/98	Janjic, et al.	536	23.1	
	*A5	5,834,166	11/10/98	George, et al.	435	6	
PS	*A6	6,083,696	07/04/00	Biesecker, et al.	435	6	
PS	*A7	6,232,071 B1	05/15/01	Hicke, et al.,	435	6	
U.S. PUBLISHED APPLICATION DOCUMENTS							
Exam Initials	Cite No.	U.S. Published Application No.	Published Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
	*A8	2002/0034506 A1	03/21/02	Pietras, et al.	424	94.63	
FOREIGN PATENT DOCUMENTS							
Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No		
	*B1	WO 98/08974	INTELLIGENE LTD.	03/05/98			
	*B2	WO 98/27104	YALE UNIVERSITY	06/25/98			
	*B3	WO 99/31276	NEXSTAR PHARMACEUTICALS, INC.	06/24/99			
	*B4	WO 00/70929	BRANDEIS UNIVERSITY	11/23/00			
	*B5	WO 01/66721 A2	RIBOZYME PHARMACEUTICALS, INC.	09/13/01			
	*B6	WO 02/22882 A2	ARCHEMIX CORPORATION	03/21/02			
	*B7	WO 03/014375 A2	ARCHEMIX CORPORATION	02/20/03			
OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS							
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.					
	*C1	Breaker, R.R., Curr. Opin. Biotech., 7:442-448 (1996).					
	*C2	Breaker, R.R., Chem. Rev., 97:371-390 (1997).					
	*C3	Breaker, R.R., Curr. Opin. Chem. Biol., 1:26-31 (1997).					
	*C4	Breaker, R.R., Nat. Biotech., 15:427-431 (1997).					
	*C5	Breaker, R.R., Intracellular Ribozyme Applications in Principles and Protocols, pgs. 1-19; Horizon Scientific Press, Wymondham UK, Rossl and Couture, eds., (1999).					
	*C6	Breaker, R.R., Curr. Opin. Biotech., 13:31-39 (2002).					
	*C7	Carmi, et al. Chem. & Biol., 3:1039-1046 (1996).					
	*C8	Gold, L., Nat. Biotech., 20: 671-672 (2002).					
	*C9	Hamaguchi, et al., Anal. Biochem., 294:126-131 (2001).					

	*C10	Hartig, et al., <i>Nat. Biotech.</i>, 20:717-722 (2002).
	*C11	Jenne, et al., <i>Nat. Biotech.</i>, 19:56-61 (2001).
	*C12	Koizumi, et al., <i>Nucl. Acids Symp. Ser.</i>, 42:275-276 (1999).
	*C13	Koizumi, et al., <i>Nat. Struct. Biol.</i>, 6(11):1062-1071 (1999).
29	*C14	Lewis, et al., <i>Bioconjug. Chem.</i> , 12(2):320-324 (2001).
	*C15	Li, et al., <i>Curr. Opin. Struct. Biol.</i>, 9:315-323 (1999).
	*C16	Li, et al., <i>Proc. Natl. Acad. Sci. USA</i>, 96:2746-2751 (1999).
	*C17	Marshall, et al., <i>Nat. Struct. Biol.</i>, 6(11):992-994 (1999).
	*C18	Potyrailo, et al., <i>Anal. Chem.</i>, 70:3440-3425 (1998).
	*C19	Raddatz, et al., <i>Nucl. Acids Res.</i> , 30(21):4793-4802 (2002).
	*C20	Robertson, et al., <i>Nucl. Acids Res.</i>, 28(8):1751-1759 (2000).
	*C21	Robertson, et al., <i>Nat. Biotech.</i>, 17:62-66 (1999).
	*C22	Robertson, et al., <i>Nat. Biotech.</i> , 19:650-655 (2001).
	*C23	Saeedifar, et al., <i>Nature</i>, 364:550-553 (1993).
	*C24	Seetharaman, et al., <i>Nat. Biotech.</i>, 19:336-341 (2001).
	*C25	Selwert, et al., <i>Chem. & Biol.</i>, 7:833-843 (2000).
	*C26	Soukup, et al., <i>Proc. Natl. Acad. Sci. USA</i>, 96:3584-3589 (1999).
	*C27	Soukup, et al., <i>RNA</i>, 5:1308-1325 (1999).
	*C28	Soukup, et al., <i>Structure</i>, 7(7):783-791 (1999).
	*C29	Soukup, et al., <i>Tren. Biotech.</i>, 17:469-476 (1999).
	*C30	Soukup, et al., in <i>Ribozyme Biochem. Biotech.</i> , Eaton Publishing, Chapter 8, pgs. 149-170, Krupp & Gaur, eds.
	*C31	Soukup, et al., <i>RNA</i>, 7:524-536 (2001).
	*C32	Soukup, et al., <i>J. Mol. Biol.</i>, 298:623-632 (2000).
29	*C33	Stetsenko, et al., <i>Nucleosides, Nucleotides & Nucl. Acids</i> , 19(10-12):1751-1764 (2000).
	*C34	Tang, et al., <i>Chem. & Biol.</i>, 4:453-459 (1997).
	*C35	Tang, et al., <i>Nucl. Acids Res.</i>, 26(48):4214-4221 (1998).
	*C36	Tang, et al., <i>RNA</i>, 3:914-925 (1997).
	*C37	Trail, et al., <i>Cancer Immunol. Immunother.</i> , 52(5):328-337 (2003).
	*C38	Tung, C.H., <i>Bioconjug. Chem.</i> , 11(5):605-618 (2000).

A copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. 10/600,007, filed June 18, 2003, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	10/4/07
-----------------------	---	--------------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.